DD263992A5 - Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel - Google Patents

Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel Download PDF

Info

Publication number: DD263992A5
Authority: DD; German Democratic Republic
Prior art keywords: general formula; acid; carbon atoms; chain; straight
Prior art date: 1986-07-11

Application number

DD87304795A

Other languages

German (de)

English (en)

Inventor

Rudi Gall

Elmar Bosies

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-11

Filing date

1987-07-09

Publication date

1989-01-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6304949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD263992(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-07-09 Application filed by ��@��@��k�� filed Critical ��@��@��k��

1989-01-18 Publication of DD263992A5 publication Critical patent/DD263992A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 19
150000001875 compounds Chemical class 0.000 title claims description 28
239000003814 drug Substances 0.000 title description 2
238000004519 manufacturing process Methods 0.000 title description 2
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 20
239000001257 hydrogen Substances 0.000 claims abstract description 18
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical class OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims abstract description 15
150000003839 salts Chemical class 0.000 claims abstract description 11
125000000217 alkyl group Chemical group 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
229920006395 saturated elastomer Polymers 0.000 claims abstract description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
239000001301 oxygen Chemical group 0.000 claims abstract description 5
229910052760 oxygen Chemical group 0.000 claims abstract description 5
125000002947 alkylene group Chemical group 0.000 claims abstract description 3
-1 Cyclohexyl substituted alkyl radical Chemical class 0.000 claims description 46
239000002253 acid Chemical class 0.000 claims description 27
150000007513 acids Chemical class 0.000 claims description 12
150000005690 diesters Chemical class 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
229910052698 phosphorus Inorganic materials 0.000 claims description 9
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 8
239000011574 phosphorus Substances 0.000 claims description 7
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
150000003254 radicals Chemical class 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
150000002431 hydrogen Chemical group 0.000 claims description 5
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
230000003301 hydrolyzing effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
150000002825 nitriles Chemical class 0.000 claims description 4
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
125000005518 carboxamido group Chemical group 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
229910014033 C-OH Inorganic materials 0.000 claims 1
229910014570 C—OH Inorganic materials 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 4
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract description 4
201000008482 osteoarthritis Diseases 0.000 abstract description 4
208000010191 Osteitis Deformans Diseases 0.000 abstract description 3
208000027868 Paget disease Diseases 0.000 abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
208000027202 mammary Paget disease Diseases 0.000 abstract description 3
206010002556 Ankylosing Spondylitis Diseases 0.000 abstract description 2
206010007027 Calculus urinary Diseases 0.000 abstract description 2
230000003913 calcium metabolism Effects 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
230000011164 ossification Effects 0.000 abstract description 2
206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
208000008281 urolithiasis Diseases 0.000 abstract description 2
206010027452 Metastases to bone Diseases 0.000 abstract 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000003921 oil Substances 0.000 description 31
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 20
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000000543 intermediate Substances 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
239000000243 solution Substances 0.000 description 11
235000011121 sodium hydroxide Nutrition 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000007858 starting material Substances 0.000 description 9
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
239000007795 chemical reaction product Substances 0.000 description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
239000003054 catalyst Substances 0.000 description 6
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
239000000126 substance Substances 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
239000012442 inert solvent Substances 0.000 description 5
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 5
238000007127 saponification reaction Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000004821 distillation Methods 0.000 description 4
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
150000004682 monohydrates Chemical class 0.000 description 4
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
239000000047 product Substances 0.000 description 4
238000005245 sintering Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
IVFGIXMLURJXBZ-UHFFFAOYSA-N 1-phosphonopropylphosphonic acid Chemical compound CCC(P(O)(O)=O)P(O)(O)=O IVFGIXMLURJXBZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000002262 Schiff base Substances 0.000 description 3
150000004753 Schiff bases Chemical class 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
238000009835 boiling Methods 0.000 description 3
239000008139 complexing agent Substances 0.000 description 3
150000008282 halocarbons Chemical class 0.000 description 3
238000005984 hydrogenation reaction Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
FJDUDHYHRVPMJZ-UHFFFAOYSA-N nonan-1-amine Chemical compound CCCCCCCCCN FJDUDHYHRVPMJZ-UHFFFAOYSA-N 0.000 description 3
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
235000011837 pasties Nutrition 0.000 description 3
238000005932 reductive alkylation reaction Methods 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
ZOGOTIIKBRFGIO-UHFFFAOYSA-N 3-[methyl(propan-2-yl)azaniumyl]propanoate Chemical compound CC(C)N(C)CCC(O)=O ZOGOTIIKBRFGIO-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
GHKYCWWSFZJNDO-UHFFFAOYSA-N [1-hydroxy-3-[methyl(propan-2-yl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound CC(C)N(C)CCC(O)(P(O)(O)=O)P(O)(O)=O GHKYCWWSFZJNDO-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229920006158 high molecular weight polymer Polymers 0.000 description 2
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000000725 suspension Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
GVDZNWFGNHAZCX-UHFFFAOYSA-N 1-phenyl-n-propan-2-ylmethanimine Chemical compound CC(C)N=CC1=CC=CC=C1 GVDZNWFGNHAZCX-UHFFFAOYSA-N 0.000 description 1
OWWOMIFQTFZNGK-UHFFFAOYSA-N 1-phosphonobutylphosphonic acid Chemical compound CCCC(P(O)(O)=O)P(O)(O)=O OWWOMIFQTFZNGK-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical compound [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 description 1
OMLKBPXWZLIABU-UHFFFAOYSA-N 3-[benzyl(propyl)amino]propanoic acid Chemical compound OC(=O)CCN(CCC)CC1=CC=CC=C1 OMLKBPXWZLIABU-UHFFFAOYSA-N 0.000 description 1
IRYCXYNCNNQBAF-UHFFFAOYSA-N 3-[butan-2-yl(methyl)amino]propanoic acid Chemical compound CCC(C)N(C)CCC(O)=O IRYCXYNCNNQBAF-UHFFFAOYSA-N 0.000 description 1
JSHGELSIUFBBBL-UHFFFAOYSA-N 3-[methyl(2-methylpropyl)amino]prop-2-enoic acid Chemical compound CC(C)CN(C)C=CC(O)=O JSHGELSIUFBBBL-UHFFFAOYSA-N 0.000 description 1
QAAZBHHRUMUCOL-UHFFFAOYSA-N 3-[methyl(pentyl)amino]prop-2-enoic acid Chemical compound CCCCCN(C)C=CC(O)=O QAAZBHHRUMUCOL-UHFFFAOYSA-N 0.000 description 1
QHJWKOZWMBUASB-UHFFFAOYSA-N 3-[methyl(propyl)azaniumyl]propanoate Chemical compound CCCN(C)CCC(O)=O QHJWKOZWMBUASB-UHFFFAOYSA-N 0.000 description 1
WCRAVWLBUPCYNJ-UHFFFAOYSA-N 3-[nonyl(pentyl)amino]propanoic acid Chemical compound CCCCCCCCCN(CCC(O)=O)CCCCC WCRAVWLBUPCYNJ-UHFFFAOYSA-N 0.000 description 1
KCMRDRWRKMYIIN-UHFFFAOYSA-N 4-[methyl(nonyl)amino]butanoic acid Chemical compound CCCCCCCCCN(C)CCCC(O)=O KCMRDRWRKMYIIN-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001024304 Mino Species 0.000 description 1
XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
QZLYAZMKIKMAGP-UHFFFAOYSA-N O.O.[K].[K] Chemical compound O.O.[K].[K] QZLYAZMKIKMAGP-UHFFFAOYSA-N 0.000 description 1
XMEKHKCRNHDFOW-UHFFFAOYSA-N O.O.[Na].[Na] Chemical compound O.O.[Na].[Na] XMEKHKCRNHDFOW-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
XZHCUPDAFGAYRR-UHFFFAOYSA-N [1-hydroxy-3-[methyl(nonyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound CCCCCCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O XZHCUPDAFGAYRR-UHFFFAOYSA-N 0.000 description 1
CHCBFCDPOXDKTN-UHFFFAOYSA-N [1-hydroxy-3-[methyl(propyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound CCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O CHCBFCDPOXDKTN-UHFFFAOYSA-N 0.000 description 1
FEUBUEUKRGKSPZ-UHFFFAOYSA-N [1-hydroxy-3-[nonyl(propyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound CCCCCCCCCN(CCC)CCC(O)(P(O)(O)=O)P(O)(O)=O FEUBUEUKRGKSPZ-UHFFFAOYSA-N 0.000 description 1
FSXXLCDDQORZQE-UHFFFAOYSA-N [1-hydroxy-5-[methyl(nonyl)amino]-1-phosphonohexyl]phosphonic acid Chemical compound CCCCCCCCCN(C)C(C)CCCC(O)(P(O)(O)=O)P(O)(O)=O FSXXLCDDQORZQE-UHFFFAOYSA-N 0.000 description 1
DHGWKKUUNMJYIM-UHFFFAOYSA-N [2-[methyl(2-methylpropyl)amino]-1-phosphonoethyl]phosphonic acid Chemical compound CC(C)CN(C)CC(P(O)(O)=O)P(O)(O)=O DHGWKKUUNMJYIM-UHFFFAOYSA-N 0.000 description 1
UTKRRBJDPZNVHK-UHFFFAOYSA-N [2-[methyl(pentyl)amino]-1-phosphonoethyl]phosphonic acid Chemical compound CCCCCN(C)CC(P(O)(O)=O)P(O)(O)=O UTKRRBJDPZNVHK-UHFFFAOYSA-N 0.000 description 1
UZCGYRKZQSLHEU-UHFFFAOYSA-N [2-[methyl(propyl)amino]-1-phosphonoethyl]phosphonic acid Chemical compound CCCN(C)CC(P(O)(O)=O)P(O)(O)=O UZCGYRKZQSLHEU-UHFFFAOYSA-N 0.000 description 1
KRRIPHAMSAVMGP-UHFFFAOYSA-N [3-(dipentylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CCCCCN(CCCCC)CCC(O)(P(O)(O)=O)P(O)(O)=O KRRIPHAMSAVMGP-UHFFFAOYSA-N 0.000 description 1
NUVLUAOBTWOEGO-UHFFFAOYSA-N [3-[cyclohexyl(methyl)amino]-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(O)(P(O)(O)=O)CCN(C)C1CCCCC1 NUVLUAOBTWOEGO-UHFFFAOYSA-N 0.000 description 1
BXLXUNIMEOIHHI-UHFFFAOYSA-N [3-[methyl(nonyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound CCCCCCCCCN(C)CCC(P(O)(O)=O)P(O)(O)=O BXLXUNIMEOIHHI-UHFFFAOYSA-N 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
208000015202 calcium metabolic disease Diseases 0.000 description 1
208000022458 calcium metabolism disease Diseases 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
RDYCCMWAGARNPN-UHFFFAOYSA-N methyl 3-[butyl(methyl)amino]propanoate Chemical compound CCCCN(C)CCC(=O)OC RDYCCMWAGARNPN-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
BCMVZMXWSSTNLU-UHFFFAOYSA-N n-benzyl-n-methylnonan-1-amine Chemical compound CCCCCCCCCN(C)CC1=CC=CC=C1 BCMVZMXWSSTNLU-UHFFFAOYSA-N 0.000 description 1
XUSMAGTYLITCIN-UHFFFAOYSA-N n-benzylnonan-1-amine Chemical compound CCCCCCCCCNCC1=CC=CC=C1 XUSMAGTYLITCIN-UHFFFAOYSA-N 0.000 description 1
OUMBFMLKPJUWDQ-UHFFFAOYSA-N n-benzylpropan-1-amine Chemical compound CCCNCC1=CC=CC=C1 OUMBFMLKPJUWDQ-UHFFFAOYSA-N 0.000 description 1
GOMQAPPROMGMME-UHFFFAOYSA-N n-nonylpentanamide Chemical compound CCCCCCCCCNC(=O)CCCC GOMQAPPROMGMME-UHFFFAOYSA-N 0.000 description 1
YUIYZUGZYBDVIL-UHFFFAOYSA-N n-pentylnonan-1-amine Chemical class CCCCCCCCCNCCCCC YUIYZUGZYBDVIL-UHFFFAOYSA-N 0.000 description 1
JACMPVXHEARCBO-UHFFFAOYSA-N n-pentylpentan-1-amine Chemical compound CCCCCNCCCCC JACMPVXHEARCBO-UHFFFAOYSA-N 0.000 description 1
FLSRMWBZKWEQHA-UHFFFAOYSA-N n-propylnonan-1-amine Chemical compound CCCCCCCCCNCCC FLSRMWBZKWEQHA-UHFFFAOYSA-N 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
DUUPDCPVCHSTFF-UHFFFAOYSA-N nonane Chemical compound [CH2]CCCCCCCC DUUPDCPVCHSTFF-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
235000011118 potassium hydroxide Nutrition 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000001226 reprecipitation Methods 0.000 description 1
238000006884 silylation reaction Methods 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Luminescent Compositions (AREA)
Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
Medicinal Preparation (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Detergent Compositions (AREA)

DD87304795A 1986-07-11 1987-07-09 Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel DD263992A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19863623397 DE3623397A1 (de)	1986-07-11	1986-07-11	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number	Publication Date
DD263992A5 true DD263992A5 (de)	1989-01-18

Family

ID=6304949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87304795A DD263992A5 (de)	1986-07-11	1987-07-09	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Country Status (27)

Country	Link
US (2)	US4927814A (xx)
EP (2)	EP0252504B1 (xx)
JP (2)	JP2563954B2 (xx)
KR (2)	KR950008997B1 (xx)
AT (2)	ATE80633T1 (xx)
AU (2)	AU598279B2 (xx)
BG (1)	BG60839B2 (xx)
CA (2)	CA1296739C (xx)
CS (1)	CS265242B2 (xx)
DD (1)	DD263992A5 (xx)
DE (4)	DE3623397A1 (xx)
DK (2)	DK168629B1 (xx)
ES (2)	ES2036190T3 (xx)
FI (2)	FI87221C (xx)
GE (1)	GEP20084347B (xx)
GR (2)	GR3000616T3 (xx)
HK (1)	HK87093A (xx)
HU (2)	HU201950B (xx)
IE (2)	IE60219B1 (xx)
IL (2)	IL83148A (xx)
LU (1)	LU88844I2 (xx)
MX (1)	MX9203375A (xx)
NL (1)	NL960032I2 (xx)
NZ (2)	NZ221027A (xx)
PT (1)	PT85301B (xx)
WO (1)	WO1988000590A1 (xx)
ZA (1)	ZA874877B (xx)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
DE3623397A1 (de) *	1986-07-11	1988-01-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0317505A1 (de) *	1987-11-13	1989-05-24	Ciba-Geigy Ag	Neue Azacycloalkylalkandiphosphonsäuren
DE3881659D1 (en) *	1987-12-11	1993-07-15	Ciba Geigy Ag	Araliphatylaminoalkandiphosphonsaeuren.
US5190930A (en) *	1987-12-11	1993-03-02	Ciba-Geigy Corporation	Araliphatylaminoalkanediphosphonic acids
US5110807A (en) *	1988-12-01	1992-05-05	Ciba-Geigy Corporation	Araliphatylaminoalkanediphosphonic acids
JPH07629B2 (ja) *	1988-01-20	1995-01-11	山之内製薬株式会社	（シクロアルキルアミノ）メチレンビス（フォスフォン酸）および該化合物を有効成分とする医薬
US4933472A (en) *	1988-04-08	1990-06-12	Yamanouchi Pharmaceutical Co., Ltd.	Substituted aminomethylenebis(phosphonic acid) derivatives
DE3822650A1 (de) *	1988-07-05	1990-02-01	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP3021035B2 (ja) *	1988-11-01	2000-03-15	アーク・デベロップメント・コーポレーション	ホスホン酸及び分離におけるその使用
GB8825589D0 (en) *	1988-11-02	1988-12-07	Albright & Wilson	Purification
TW198039B (xx) *	1988-11-28	1993-01-11	Ciba Geigy Ag
US5154843A (en) *	1989-02-08	1992-10-13	The Lubrizol Corporation	Hydroxyalkane phosphonic acids and derivatives thereof and lubricants containing the same
PH26923A (en) *	1989-03-08	1992-12-03	Ciba Geigy	N-substituted amino alkanediphosphonic acids
US4987767A (en) *	1989-06-09	1991-01-29	Research Corporation Technologies, Inc.	Exposive detection screening system
MX21453A (es) *	1989-07-07	1994-01-31	Ciba Geigy Ag	Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) *	1989-07-07	1994-01-31	Ciba Geigy Ag	Preparaciones farmaceuticas que se administran en forma topica.
US5139786A (en) *	1989-07-07	1992-08-18	Ciba-Geigy Corporation	Topical formulations
US5324519A (en) *	1989-07-24	1994-06-28	Atrix Laboratories, Inc.	Biodegradable polymer composition
US5487897A (en) *	1989-07-24	1996-01-30	Atrix Laboratories, Inc.	Biodegradable implant precursor
EP0416689B1 (en) *	1989-09-06	1995-11-29	Merck & Co. Inc.	Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
US5356887A (en) *	1990-01-31	1994-10-18	Merck & Co., Inc.	Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
FI89364C (fi) *	1990-12-20	1993-09-27	Leiras Oy	Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
IT1244698B (it) *	1991-02-01	1994-08-08	Gentili Ist Spa	Acidi aril-o arilalchil-acil ammino-alchil-idrossidifosfonici, procedimento per la loro preparazione e loro uso in terapia osteo-articolare e dei tessuti connettori in generale
WO1992022559A1 (en) *	1991-06-19	1992-12-23	The Upjohn Company	Dialkyl (dialkoxyphosphinyl)methyl phosphates as anti-inflammatory agents
IT1247034B (it) *	1991-06-26	1994-12-12	Gentili Ist Spa	Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
ATE147396T1 (de) *	1991-08-27	1997-01-15	Ciba Geigy Ag	N-substituierte aminomethandiphosphonsäuren
EP0541037A3 (en) *	1991-11-06	1997-02-26	Takeda Chemical Industries Ltd	Squalene synthetase inhibitory composition and use thereof
DE4228552A1 (de) *	1992-08-27	1994-03-03	Boehringer Mannheim Gmbh	Diphosphonsäuren und deren Salze enthaltende Arzneimittel
EP0600834A1 (en) *	1992-11-30	1994-06-08	Ciba-Geigy Ag	Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en)	1992-11-30	1996-07-11	Novartis Ag	Use of certain methanebisphosphonic acid derivatives in fracture healing
US5358941A (en) *	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
EP0600371B1 (de) *	1992-12-02	1999-02-03	Hoechst Aktiengesellschaft	Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US6406714B1 (en)	1992-12-02	2002-06-18	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids
WO1994014455A1 (en) *	1992-12-23	1994-07-07	Merck & Co., Inc.	Bisphosphonate/estrogen therapy for treating and preventing bone loss
US6399592B1 (en)	1992-12-23	2002-06-04	Merck & Co., Inc.	Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5728650A (en) *	1993-10-07	1998-03-17	Zeneca Limited	Herbicidal aza bisphosphonic acids and compositions containing the same
TW401276B (en) *	1993-10-07	2000-08-11	Zeneca Ltd	Novel compounds and a method of controlling growth of plants
US5591730A (en) *	1993-10-12	1997-01-07	The Regents Of The University Of California	Inhibition of urinary calculi growth
US5681873A (en) *	1993-10-14	1997-10-28	Atrix Laboratories, Inc.	Biodegradable polymeric composition
US20010007863A1 (en) *	1998-06-18	2001-07-12	Merck & Co., Inc.	Wet granulation formulation for bisphosphonic acids
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations
WO1996039107A1 (en)	1995-06-06	1996-12-12	Merck & Co., Inc.	Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP0753523A1 (en) *	1995-07-10	1997-01-15	Gador S.A.	Amino-substituted bisphosphonic acids
DE69634487T2 (de) *	1995-09-29	2006-01-05	Novartis Ag	Verfahren zur behandlung navikularer krankheiten bei pferden
GB9607945D0 (en) *	1996-04-17	1996-06-19	Univ Nottingham	Bisphosponates as Anti-inflammatory agents
DE19615812A1 (de) *	1996-04-20	1997-10-23	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
KR100192215B1 (ko) *	1996-09-03	1999-06-15	강재헌	3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
DE19719680A1 (de)	1997-05-09	1998-11-19	Boehringer Mannheim Gmbh	Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US6432932B1 (en)	1997-07-22	2002-08-13	Merck & Co., Inc.	Method for inhibiting bone resorption
US5994329A (en)	1997-07-22	1999-11-30	Merck & Co., Inc.	Method for inhibiting bone resorption
US6187329B1 (en)	1997-12-23	2001-02-13	Board Of Regents Of The University Of Texas System	Variable permeability bone implants, methods for their preparation and use
US6255359B1 (en)	1997-12-23	2001-07-03	Board Of Regents Of The University Of Texas System	Permeable compositions and methods for their preparation
CN1061661C (zh) *	1997-12-24	2001-02-07	国家医药管理局上海医药工业研究院	(环庚基胺基)亚甲基二膦酸二钠一水合物制备方法
US20020128301A1 (en) *	1998-02-13	2002-09-12	Medivir AB	Non-nucleoside reverse transcriptase inhibitors
US6733767B2 (en)	1998-03-19	2004-05-11	Merck & Co., Inc.	Liquid polymeric compositions for controlled release of bioactive substances
US7128927B1 (en)	1998-04-14	2006-10-31	Qlt Usa, Inc.	Emulsions for in-situ delivery systems
EP0998932A1 (de)	1998-10-09	2000-05-10	Boehringer Mannheim Gmbh	Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de)	1998-10-09	2000-05-10	Boehringer Mannheim Gmbh	Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
AU756540B2 (en)	1998-12-04	2003-01-16	Roche Diagnostics Gmbh	Use of ibandronate for promoting osseointegration of endoprostheses
IL146520A0 (en) *	1999-05-21	2002-07-25	Novartis Ag	Use of bisphosphonic acids for treating angiogenesis
AR024462A1 (es)	1999-07-01	2002-10-02	Merck & Co Inc	Tabletas farmaceuticas
US8226598B2 (en) *	1999-09-24	2012-07-24	Tolmar Therapeutics, Inc.	Coupling syringe system and methods for obtaining a mixed composition
AR021347A1 (es)	1999-10-20	2002-07-17	Cipla Ltd	Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6677320B2 (en)	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
US6562974B2 (en)	2000-02-01	2003-05-13	The Procter & Gamble Company	Process for making geminal bisphosphonates
US6410520B2 (en)	2000-02-01	2002-06-25	The Procter & Gamble Company	Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
SE0000382D0 (sv)	2000-02-07	2000-02-07	Astrazeneca Ab	New process
ATE314862T1 (de)	2000-05-05	2006-02-15	Hoffmann La Roche	Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
TWI315982B (en) *	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
IL162053A0 (en) *	2001-12-21	2005-11-20	Procter & Gamble	Method for the treatment of bone disorders
US20050070504A1 (en) *	2001-12-21	2005-03-31	The Procter & Gamble Co.	Risedronate compositions and their methods of use
CA2472578A1 (en) *	2002-01-24	2003-07-31	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Anti-cancer combination and use thereof
CA2480814A1 (en) *	2002-04-05	2003-10-23	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
CA2481142C (en) *	2002-05-10	2012-11-13	F.Hoffmann-La Roche Ag	Bisphosphonic acids for the treatment and prevention of osteoporosis
CN1665825A (zh) *	2002-05-17	2005-09-07	特瓦制药工业有限公司	用一定的稀释剂制备双膦酸
WO2003103664A1 (en) *	2002-06-06	2003-12-18	Merck Frosst Canada & Co.	1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
JP2006504679A (ja) *	2002-08-28	2006-02-09	メルクフロストカナダアンドカンパニー	緑内障の治療においてｅｐ４受容体作動薬として使用するためのオキサゾリジン−２−オンおよびチアゾリジン−２−オン誘導体
US20040138180A1 (en) *	2002-10-03	2004-07-15	Barr Laboratories, Inc.	Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) *	2002-11-20	2004-05-20	Wimalawansa Sunil J.	Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
SI1596870T2 (sl) *	2002-12-20	2011-07-29	Hoffmann La Roche	Formulacija z visokim odmerkom ibandronata
CA2513543A1 (en) *	2003-01-17	2004-08-05	Teva Pharmaceutical Industries Ltd.	Risedronate sodium having a very low content of iron
JP4553899B2 (ja)	2003-08-21	2010-09-29	メルクフロストカナダリミテツド	カテプシンシステインプロテアーゼ阻害剤
DE602004024545D1 (de) *	2003-08-21	2010-01-21	Sun Pharmaceuticals Ind Ltd	Indungen
KR20060058134A (ko) *	2003-09-19	2006-05-29	화이자 프로덕츠 인코포레이티드	2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
EP2206717B1 (en)	2003-12-23	2013-03-27	Alchymars S.p.A.	A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2005090370A1 (en)	2004-02-05	2005-09-29	The Regents Of The University Of California	Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
PT2283825T (pt)	2004-05-24	2022-06-30	Theramex Hq Uk Ltd	Forma de dosagem oral entérica sólida de um bisfosfonato contendo um agente quelante
UA87854C2 (xx)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
MX2007000087A (es) *	2004-06-23	2007-11-06	Teva Pharma	Acido ibandronico solido y cristalino.
EP1713489B1 (en) *	2004-08-23	2011-01-19	Teva Pharmaceutical Industries Ltd	Crystalline form of ibandronate sodium and processes for preparation thereof
WO2008128056A1 (en) *	2004-10-08	2008-10-23	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1802641B8 (en) *	2004-10-08	2012-03-07	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) *	2006-03-17	2010-03-30	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods
US7214818B2 (en) *	2004-10-29	2007-05-08	Hoffmann-La Roche Inc.	Method for synthesizing bisphosphonate
EP1832293A4 (en) *	2004-12-10	2009-01-07	Tmrc Co Ltd	MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT
US7582789B2 (en) *	2005-02-01	2009-09-01	Hoffmann-La Roche Inc.	Ibandronate polymorph
CN101111504B (zh) *	2005-02-01	2011-12-21	霍夫曼-拉罗奇有限公司	伊班膦酸盐多晶型物a
PT1855674E (pt)	2005-03-02	2014-10-08	Merck Canada Inc	Composição para a inibição de catepsina k
EP1865928A1 (en) *	2005-03-17	2007-12-19	Elan Pharma International Limited	Nanoparticulate biphosphonate compositions
EP2842559A3 (en)	2005-04-08	2015-03-18	Chimerix, Inc.	Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006110655A2 (en)	2005-04-08	2006-10-19	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
WO2007013097A1 (en) *	2005-07-25	2007-02-01	Natco Pharma Limited	Improved process for the preparation of ibandronate sodium
US8362086B2 (en)	2005-08-19	2013-01-29	Merial Limited	Long acting injectable formulations
US20070049557A1 (en) *	2005-08-24	2007-03-01	Hashim Ahmed	Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
WO2007074475A2 (en) *	2005-12-27	2007-07-05	Natco Pharma Limited	Novel polymorphic forms of ibandronate
US20070191315A1 (en) *	2006-02-16	2007-08-16	Bengt Bergstrom	Method for administering ibandronate
JP5571378B2 (ja) *	2006-06-23	2014-08-13	シプラ・リミテッド	イバンドロン酸ナトリウムの合成方法
US10875826B2 (en)	2006-09-07	2020-12-29	Emisphere Technologies, Inc.	Process for the manufacture of SNAC (salcaprozate sodium)
EP1966227A1 (en)	2006-11-16	2008-09-10	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ibandronate sodium
US20080139514A1 (en) *	2006-11-29	2008-06-12	Subhash Pandurang Gore	Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) *	2006-12-12	2008-06-12	Apotex Pharmachem Inc.	Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
JP5290198B2 (ja) *	2006-12-20	2013-09-18	ミランファーマシューティカルズユーエルシー	ホットメルト顆粒化潤滑剤を含んでなる医薬組成物
AU2007335155A1 (en)	2006-12-20	2008-06-26	Mylan Pharmaceuticals Ulc	A composition containing a bisphosphonic acid in combination with vitamin D
WO2008116133A1 (en) *	2007-03-21	2008-09-25	Duke University	Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
PL2144919T3 (pl) *	2007-04-11	2016-05-31	Hoffmann La Roche	Wieloetapowa synteza ibandronianu
EP2203460A4 (en) *	2007-04-12	2012-03-14	Univ Illinois	BIPHOSPHONATE COMPOUNDS AND METHODS WITH INCREASED POTENTIAL FOR MULTIPLE OBJECTIVES, INCLUDING FPPS, GGPPS AND DPPS
KR20100014728A (ko)	2007-04-19	2010-02-10	닥터 레디스 레보러터리즈 리미티드	이반드로네이트 나트륨 다형태
WO2009020483A1 (en) *	2007-08-09	2009-02-12	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ibandronate sodium
JP2010536437A (ja)	2007-08-15	2010-12-02	カーディオデックスリミテッド	穿刺を閉塞するためのシステムおよび方法
US20090075944A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched ibandronate
US20090099390A1 (en) *	2007-09-24	2009-04-16	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ibandronic acid and processes for the preparation thereof
EP2128166A1 (en)	2008-05-20	2009-12-02	Chemo Ibérica, S.A.	Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) *	2007-11-05	2009-05-14	Teva Pharmaceutical Industries Ltd.	Amorphous and crystalline forms of ibandronate disodium
CA2708281A1 (en)	2007-12-11	2009-08-27	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP5539221B2 (ja)	2007-12-21	2014-07-02	リガンド・ファーマシューティカルズ・インコーポレイテッド	選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
WO2009093258A2 (en) *	2008-01-24	2009-07-30	Fleming Laboratories Limited	A new and improved process for the preparation of ibandronate sodium monohydrate
ES2572631T3 (es) *	2008-01-25	2016-06-01	Chimerix, Inc.	Métodos de tratamiento de infecciones virales
WO2010035664A1 (ja) *	2008-09-24	2010-04-01	田辺三菱製薬株式会社	ビスホスホン酸誘導体の製法
EP2180003A1 (en)	2008-10-21	2010-04-28	Zentiva, k.s.	Preparation of ibandronate trisodium
EP2210596A1 (en)	2009-01-22	2010-07-28	Laboratorios Liconsa, S.A.	Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
GB0906068D0 (en)	2009-04-07	2009-05-20	King S College London	Bisphosphonate Compounds for chelating radionuclides
WO2010143193A1 (en)	2009-06-11	2010-12-16	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Targeted liposomes comprising n-containing bisphosphonates and uses thereof
WO2011011519A1 (en)	2009-07-21	2011-01-27	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
US20120164104A1 (en)	2009-08-03	2012-06-28	Chimerix, Inc.	Composition and Methods of Treating Viral Infections and Viral Induced Tumors
WO2011016738A1 (en)	2009-08-05	2011-02-10	Zaklady Farmaceutyczne Polpharma Sa	A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
EP2473172B1 (en)	2009-09-01	2015-04-08	Duke University	Bisphosphonate compositions and methods for treating heart failure
FR2954320B1 (fr)	2009-12-17	2012-06-15	Cll Pharma	Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
EP3216789A1 (en)	2010-02-12	2017-09-13	Chimerix, Inc.	Methods of treating viral infection
EP2563367A4 (en)	2010-04-26	2013-12-04	Chimerix Inc	METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
WO2012007021A1 (en)	2010-07-14	2012-01-19	Pharmathen S.A.	Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
TR201100151A2 (tr)	2011-01-06	2012-07-23	Bi̇lgi̇ç Mahmut	İbandronate formülasyonu.
WO2012112363A1 (en)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
RS61235B1 (sr)	2011-07-13	2021-01-29	Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd	Lipozomi koji ko-inkapsuliraju bisfosfonat i amfipatički agens
JP6261512B2 (ja)	2011-11-16	2018-01-17	デュークユニバーシティ	心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法
US8748097B1 (en)	2011-12-02	2014-06-10	President And Fellows Of Harvard College	Identification of agents for treating calcium disorders and uses thereof
TR201200588A2 (tr)	2012-01-18	2012-07-23	Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇	Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
GB201200868D0 (en)	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition
CN103396332A (zh) *	2013-08-19	2013-11-20	四川协力制药有限公司	3—[（n—甲基—n—戊基）氨基]丙酸盐酸盐的制备方法
EP3055314B1 (en)	2013-10-08	2018-09-12	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015051479A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
WO2015120580A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Cathepsin cysteine protease inhibitors
PL407922A1 (pl)	2014-04-16	2015-10-26	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością	Nowe bisfosfoniany i ich zastosowanie
JP6649902B2 (ja)	2014-05-30	2020-02-19	ファイザー・インク	選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
US20210008084A1 (en)	2017-10-16	2021-01-14	Tsinghua University	Mevalonate pathway inhibitor and pharmaceutical composition thereof
KR20200085441A (ko)	2019-01-07	2020-07-15	엠에프씨 주식회사	이반드로네이트의 신규한 결정형 및 이의 제조방법
KR20220115062A (ko)	2021-02-09	2022-08-17	(주)오스티오뉴로젠	크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH9776A (en) *	1967-12-11	1976-03-17	M Francis	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3733270A (en) *	1971-03-08	1973-05-15	Monsanto Co	Methods of scale inhibition
DE2405254C2 (de) *	1974-02-04	1982-05-27	Henkel KGaA, 4000 Düsseldorf	Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) *	1974-02-04	1979-01-16	Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa)	Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2534391C2 (de) *	1975-08-01	1983-01-13	Henkel KGaA, 4000 Düsseldorf	1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
SU739076A1 (ru) *	1976-05-19	1980-06-05	Институт Химической Кинетики И Горения Со Ан Ссср	Способ получени -аминоэтилидендифосфоновых кислот
DE2702631A1 (de) *	1977-01-22	1978-07-27	Henkel Kgaa	Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) *	1979-10-27	1983-01-27	Henkel KGaA, 4000 Düsseldorf	Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
SU1002300A1 (ru) *	1981-10-29	1983-03-07	Ордена Ленина институт элементоорганических соединений им.А.Н.Несмеянова	Способ получени @ -аминозамещенных- @ -оксипропилидендифосфоновых кислот
EP0085321B1 (de) *	1982-01-27	1986-08-27	Schering Aktiengesellschaft	Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
EP0096931B1 (en) *	1982-06-10	1987-03-25	Mallinckrodt, Inc. (a Delaware corporation)	Radiographic imaging agents
DE3434667A1 (de) *	1984-09-21	1986-04-03	Henkel KGaA, 4000 Düsseldorf	4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3540150A1 (de) *	1985-11-13	1987-05-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) *	1986-07-11	1988-01-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

1986
- 1986-07-11 DE DE19863623397 patent/DE3623397A1/de not_active Withdrawn
1987
- 1987-07-06 ZA ZA874877A patent/ZA874877B/xx unknown
- 1987-07-07 DK DK350987A patent/DK168629B1/da not_active IP Right Cessation
- 1987-07-07 CS CS875157A patent/CS265242B2/cs not_active IP Right Cessation
- 1987-07-07 AU AU75291/87A patent/AU598279B2/en not_active Expired
- 1987-07-09 IL IL83148A patent/IL83148A/xx not_active IP Right Cessation
- 1987-07-09 WO PCT/EP1987/000368 patent/WO1988000590A1/de active IP Right Grant
- 1987-07-09 IL IL83149A patent/IL83149A/xx unknown
- 1987-07-09 AT AT87109900T patent/ATE80633T1/de not_active IP Right Cessation
- 1987-07-09 EP EP87109899A patent/EP0252504B1/de not_active Expired - Lifetime
- 1987-07-09 ES ES198787109899T patent/ES2036190T3/es not_active Expired - Lifetime
- 1987-07-09 DD DD87304795A patent/DD263992A5/de not_active IP Right Cessation
- 1987-07-09 DE DE8787109899T patent/DE3763314D1/de not_active Expired - Lifetime
- 1987-07-09 LU LU88844C patent/LU88844I2/fr unknown
- 1987-07-09 KR KR1019880700274A patent/KR950008997B1/ko not_active IP Right Cessation
- 1987-07-09 AU AU76487/87A patent/AU598569B2/en not_active Ceased
- 1987-07-09 US US07/071,471 patent/US4927814A/en not_active Expired - Lifetime
- 1987-07-09 HU HU873826A patent/HU201950B/hu not_active IP Right Cessation
- 1987-07-09 DE DE8787109900T patent/DE3781730D1/de not_active Expired - Lifetime
- 1987-07-09 ES ES87109900T patent/ES2043622T3/es not_active Expired - Lifetime
- 1987-07-09 AT AT87109899T patent/ATE54000T1/de active
- 1987-07-09 US US07/071,320 patent/US4942157A/en not_active Expired - Fee Related
- 1987-07-09 DE DE1996175038 patent/DE19675038I2/de active Active
- 1987-07-09 EP EP87109900A patent/EP0252505B1/de not_active Expired - Lifetime
- 1987-07-09 JP JP62503985A patent/JP2563954B2/ja not_active Expired - Lifetime
- 1987-07-10 HU HU873158A patent/HU199856B/hu unknown
- 1987-07-10 FI FI873058A patent/FI87221C/fi not_active IP Right Cessation
- 1987-07-10 NZ NZ221027A patent/NZ221027A/en unknown
- 1987-07-10 CA CA000541755A patent/CA1296739C/en not_active Expired - Lifetime
- 1987-07-10 KR KR1019870007485A patent/KR960010418B1/ko not_active IP Right Cessation
- 1987-07-10 IE IE186287A patent/IE60219B1/en not_active IP Right Cessation
- 1987-07-10 IE IE186187A patent/IE60345B1/en not_active IP Right Cessation
- 1987-07-10 JP JP62171350A patent/JPH082913B2/ja not_active Expired - Lifetime
- 1987-07-10 NZ NZ221028A patent/NZ221028A/xx unknown
- 1987-07-10 CA CA000541756A patent/CA1305166C/en not_active Expired - Lifetime
- 1987-07-10 PT PT85301A patent/PT85301B/pt unknown
1988
- 1988-03-01 DK DK109688A patent/DK164281C/da active
- 1988-03-10 FI FI881134A patent/FI85026C/fi not_active IP Right Cessation
1990
- 1990-06-29 GR GR90400428T patent/GR3000616T3/el unknown
1992
- 1992-06-25 MX MX9203375A patent/MX9203375A/es active IP Right Grant
- 1992-09-17 GR GR900400208T patent/GR3005709T3/el unknown
1993
- 1993-08-26 HK HK870/93A patent/HK87093A/xx not_active IP Right Cessation
1994
- 1994-02-28 BG BG098610A patent/BG60839B2/bg unknown
1996
- 1996-12-19 NL NL960032C patent/NL960032I2/nl unknown
2006
- 2006-06-21 GE GEAP20069467A patent/GEP20084347B/en unknown

Also Published As

Publication number	Publication date
DE3763314D1 (de)	1990-07-26
HUT47300A (en)	1989-02-28
JPH01500266A (ja)	1989-02-02
EP0252504B1 (de)	1990-06-20
EP0252504A1 (de)	1988-01-13
DK350987A (da)	1988-01-12
AU598569B2 (en)	1990-06-28
WO1988000590A1 (en)	1988-01-28
GEP20084347B (en)	2008-04-10
MX9203375A (es)	1992-09-01
ATE80633T1 (de)	1992-10-15
IE60345B1 (en)	1994-06-29
FI85026C (fi)	1992-02-25
EP0252505B1 (de)	1992-09-16
ES2036190T3 (es)	1993-05-16
BG60839B2 (bg)	1996-04-30
HU199856B (en)	1990-03-28
ES2043622T3 (es)	1994-01-01
US4927814A (en)	1990-05-22
FI873058A0 (fi)	1987-07-10
NL960032I2 (nl)	1997-08-01
IL83149A (en)	1992-07-15
IE60219B1 (en)	1994-06-15
NZ221028A (en)	1990-09-26
IE871861L (en)	1988-01-11
GR3005709T3 (xx)	1993-06-07
ATE54000T1 (de)	1990-07-15
DK164281B (da)	1992-06-01
FI87221B (fi)	1992-08-31
FI87221C (fi)	1992-12-10
KR960010418B1 (ko)	1996-07-31
DE3623397A1 (de)	1988-01-14
IL83148A0 (en)	1987-12-31
CS515787A2 (en)	1989-01-12
IL83149A0 (en)	1987-12-31
DK168629B1 (da)	1994-05-09
DE19675038I2 (de)	2001-08-09
JP2563954B2 (ja)	1996-12-18
DE3781730D1 (de)	1992-10-22
EP0252505A1 (de)	1988-01-13
AU598279B2 (en)	1990-06-21
FI881134A0 (fi)	1988-03-10
PT85301B (pt)	1990-03-30
JPS6323889A (ja)	1988-02-01
FI873058A (fi)	1988-01-12
HK87093A (en)	1993-09-03
CA1296739C (en)	1992-03-03
JPH082913B2 (ja)	1996-01-17
GR3000616T3 (en)	1991-09-27
KR950008997B1 (ko)	1995-08-10
AU7648787A (en)	1988-02-10
DK109688D0 (da)	1988-03-01
HU201950B (en)	1991-01-28
NZ221027A (en)	1990-11-27
DK164281C (da)	1992-11-16
HUT44569A (en)	1988-03-28
CA1305166C (en)	1992-07-14
ZA874877B (xx)	1988-01-13
US4942157A (en)	1990-07-17
PT85301A (de)	1987-08-01
NL960032I1 (nl)	1997-03-03
DK350987D0 (da)	1987-07-07
IL83148A (en)	1993-02-21
FI881134A (fi)	1988-03-10
KR880001687A (ko)	1988-04-26
KR880701726A (ko)	1988-11-04
AU7529187A (en)	1988-01-14
IE871862L (en)	1988-01-11
CS265242B2 (en)	1989-10-13
FI85026B (fi)	1991-11-15
DK109688A (da)	1988-03-01
LU88844I2 (fr)	1997-01-06

Publication	Publication Date	Title
EP0252504B1 (de)	1990-06-20	Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0224751B1 (de)	1990-01-24	Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0350002B1 (de)	1993-01-13	Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0273190B1 (de)	1991-04-17	Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindung enthaltende Arzneimittel
DE3626058A1 (de)	1988-02-11	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CH646979A5 (de)	1984-12-28	Verfahren zur herstellung neuer hydroxylamin-substituierter aliphatischer phosphonsaeuren.
EP0546548B1 (de)	1997-05-02	Guanidinalkyl-1,1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0371921B1 (de)	1994-06-08	Phenylaliphatylaminoalkandi-phosphonsäuren
DE69022593T2 (de)	1996-06-13	Neue methylenbisphosphonsäurederivate.
EP0473626B1 (de)	1993-12-01	Neue diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE2038835C3 (de)	1981-04-16	1,10-Bis(carboxyalkylen-thio)-decane, deren Herstellung und Verwendung
DE4029499A1 (de)	1992-03-19	Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0651757A1 (de)	1995-05-10	Neue acyclische amidingruppen-haltige diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
EP0752999B1 (de)	1998-10-28	Neue 2.4-diphosphonoglutarsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE68904909T2 (de)	1993-05-27	N-heterocyclische propyliden-1,1-biphosphonsaeuren, ihre herstellung und eine pharmazeutische verbindung.
AT367429B (de)	1982-07-12	Verfahren zur herstellung von neuen hydroxylamino-hydrocarbylphosphonsaeurederivaten
DE4320223A1 (de)	1994-12-22	Neue Phosphonobernsteinsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2240229C2 (de)	1982-06-24	Phosphorsäureester oder deren funktionelle Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Erforschung der Prostaglandinwirkung
DE2011092A1 (de)	1970-09-17	Herstellung von Phosphonsäuren

Legal Events

Date	Code	Title	Description
2001-02-15	ENJ	Ceased due to non-payment of renewal fee